Last $16.57 USD
Change Today -0.61 / -3.55%
Volume 212.3K
PETX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Open
$16.98
Previous Close
$17.18
Day High
$17.49
Day Low
$16.54
52 Week High
02/11/14 - $25.50
52 Week Low
10/2/14 - $9.20
Market Cap
575.1M
Average Volume 10 Days
215.4K
EPS TTM
$-0.63
Shares Outstanding
34.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARATANA THERAPEUTICS INC (PETX)

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide. Its product portfolio includes approximately 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a ghrelin agonist for inappetence in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs. It also develops AT-004, a monoclonal antibody (MAB) used in the treatment of canine B-cell lymphoma; and AT-005, a MAB for the treatment of canine T-cell lymphoma in pets. The company was founded in 2010 and is headquartered in Kansas City, Kansas.

25 Employees
Last Reported Date: 03/26/14
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $50.7K
Chief Development Officer
Total Annual Compensation: $286.1K
Chief Commercial Officer
Total Annual Compensation: $270.6K
Chief Scientific Officer
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2013.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutic Seeks Acquisitions

Steven St. Peter, Managing Director, President and Chief Executive Officer of Aratana Therapeutics, Inc. (NasdaqGM:PETX), commented, "The 'Best Pipeline 2014' award from Animal Pharm is very gratifying for Aratana as it highlights our ability to take a truly unique vision – transforming the pet therapeutics industry through the development and commercialization of innovative biopharmaceutical products – and make it a reality. Today, Aratana has a diversified pipeline consisting of biologics and small molecules targeting multiple therapeutic indications for dogs and cats, each of which represents a potential breakthrough for veterinary medicine. Looking ahead, we are focused on advancing our pipeline and commercial operations, while continuing to expand our portfolio via potential in-licensing and acquisition opportunities."

Aratana Therapeutics, Inc. Receives Full License for AT-004 from U.S. Department of Agriculture

Aratana Therapeutics, Inc. announced that AT-004, the company's canine-specific monoclonal antibody targeting CD20 as an aid in the treatment of B-cell lymphoma in dogs, has received a full license from the U.S. Department of Agriculture. Aratana believes that this represents the only full license for a species-specific monoclonal antibody within the animal health industry. AT-004 is exclusively partnered with a third party for commercialization in the United States and Canada. Aratana retains development and commercial rights for AT-004 in other geographies. B-cell lymphoma is a common cancer in dogs, and is a devastating disease that can progress very quickly if left untreated. A Chemotherapy, although never specifically approved by regulatory authorities for use in dogs, is often the primary treatment. Nearly all dogs suffer significant side effects from chemotherapy and ultimately relapse, leaving a significant need for new treatment options. Aratana's biologics portfolio also includes, AT-005, a canine lymphoma monoclonal antibody targeting CD52 as an aid in the treatment of T-cell lymphoma in dogs, which received a conditional license from the USDA in January 2014. Aratana also submitted AT-014, a novel cancer immunotherapy for canine osteosarcoma, for a product license with the USDA. With its combination of monoclonal antibodies and immunotherapies, Aratana is an industry pioneer with a significant intellectual property estate and two products already available on the market.

Aratana Therapeutics, Inc.(NasdaqGM:PETX) added to NASDAQ Biotechnology Index

Aratana Therapeutics, Inc. will be added to the NASDAQ Biotechnology Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $16.57 USD -0.61

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $6.31 USD -0.38
View Industry Companies
 

Industry Analysis

PETX

Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 757.5x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 703.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit www.aratana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.